Hemagglutinin-esterase cannot be considered as a candidate for designing drug against COVID-19
- PMID: 34241772
- PMCID: PMC8267763
- DOI: 10.1007/s11030-021-10272-w
Hemagglutinin-esterase cannot be considered as a candidate for designing drug against COVID-19
Abstract
We read with interest the article by Patel et al. on the identification of potential inhibitors of coronavirus hemagglutinin-esterase. The authors considered hemagglutinin-esterase as a glycoprotein of SARS-CoV-2 and selected hemagglutinin-esterase as a target to identify potential inhibitors using a combination of various computational approaches, and however, SARS-CoV-2 genome lacks hemagglutinin-esterase gene; thus, hemagglutinin-esterase does not exist in SARS-CoV-2 particle.
Keywords: Betacoronavirus; Genome; Hemagglutinin-esterase; SARS-CoV-2.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Conflict of interest statement
Authors declare no conflicts of interest.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
